title: [Progress of pediatric nephrology].
authors.forename: Shuji
authors.initials: S
authors.lastname: Kondo
authors.forename: Maki
authors.initials: M
authors.lastname: Urushihara
authors.forename: Shoji
authors.initials: S
authors.lastname: Kagami
mesh_terms: D000804:Angiotensin II / Q000652:urine; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D015415:Biomarkers / Q000652:urine; D002648:Child; D002986:Clinical Trials as Topic; D042241:Early Diagnosis; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007668:Kidney / Q000002:abnormalities; D019808:Losartan / Q000627:therapeutic use; D009154:Mutation; D018995:Myosin Heavy Chains / Q000235:genetics; D009404:Nephrotic Syndrome / Q000188:drug therapy / Q000235:genetics; D009419:Nerve Tissue Proteins / Q000235:genetics; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D000069283:Rituximab; D014551:Urinary Tract / Q000002:abnormalities
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D058846:Antibodies, Monoclonal, Murine-Derived; D015415:Biomarkers; D007155:Immunologic Factors; D009419:Nerve Tissue Proteins; D000804:Angiotensin II; D000069283:Rituximab; D018995:Myosin Heavy Chains; D019808:Losartan